Literature DB >> 8740311

Glial fibrillary acidic protein is increased in the cerebrospinal fluid of preterm infants with abnormal neurological findings.

M Blennow1, L Rosengren, S Jonsson, H Forssberg, M Katz-Salamon, H Hagberg, U Hesser, H Lagercrantz.   

Abstract

Glial fibrillary acidic protein (GFAP) is the structural protein of the intermediate filament of astroglia. The aims of the present study were to examine GFAP in the cerebrospinal fluid (CSF) of preterm infants at different postmenstrual ages and to evaluate the potential of GFAP to predict abnormal neurodevelopmental outcome. GFAP increased in correlation with postmenstrual age in preterm infants (n = 17) and full-term infants (n = 9). The levels were five times higher in preterm infants (n = 10) with an abnormal neonatal course and/or an abnormal neurological outcome than in healthy preterm infants. The positive predictive value of a GFAP higher than the 98th percentile of normal infants was 69%, while a GFAP level below this limit invariable predicted a good outcome. Simultaneously analysed noradrenaline, hypoxanthine and glutamate did not differ between the groups. We conclude that CSF GFAP increases with maturity and that CSF GFAP appears to be a promising marker for perinatal brain damage.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8740311     DOI: 10.1111/j.1651-2227.1996.tb14068.x

Source DB:  PubMed          Journal:  Acta Paediatr        ISSN: 0803-5253            Impact factor:   2.299


  7 in total

1.  Brain specific proteins in posthaemorrhagic ventricular dilatation.

Authors:  A Whitelaw; L Rosengren; M Blennow
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2001-03       Impact factor: 5.747

Review 2.  Perinatal biomarkers in prematurity: early identification of neurologic injury.

Authors:  Maria Andrikopoulou; Ahmad Almalki; Azadeh Farzin; Christina N Cordeiro; Michael V Johnston; Irina Burd
Journal:  Int J Dev Neurosci       Date:  2014-04-24       Impact factor: 2.457

3.  αII-spectrin breakdown products (SBDPs): diagnosis and outcome in severe traumatic brain injury patients.

Authors:  Stefania Mondello; Steven A Robicsek; Andrea Gabrielli; Gretchen M Brophy; Linda Papa; Joseph Tepas; Claudia Robertson; Andras Buki; Dancia Scharf; Mo Jixiang; Linnet Akinyi; Uwe Muller; Kevin K W Wang; Ronald L Hayes
Journal:  J Neurotrauma       Date:  2010-07       Impact factor: 5.269

Review 4.  Dysfunctions of neuronal and glial intermediate filaments in disease.

Authors:  Ronald K H Liem; Albee Messing
Journal:  J Clin Invest       Date:  2009-07-01       Impact factor: 14.808

5.  How does extracerebral trauma affect the clinical value of S100B measurements?

Authors:  Søren Ohrt-Nissen; Lennart Friis-Hansen; Benny Dahl; Jakob Stensballe; Bertil Romner; Lars S Rasmussen
Journal:  Emerg Med J       Date:  2010-10-14       Impact factor: 2.740

Review 6.  Use of early biomarkers in neonatal brain damage and sepsis: state of the art and future perspectives.

Authors:  Iliana Bersani; Cinzia Auriti; Maria Paola Ronchetti; Giusi Prencipe; Diego Gazzolo; Andrea Dotta
Journal:  Biomed Res Int       Date:  2015-01-18       Impact factor: 3.411

7.  Recommendations to enable drug development for inherited neuropathies: Charcot-Marie-Tooth and Giant Axonal Neuropathy.

Authors:  Lori Sames; Allison Moore; Renee Arnold; Sean Ekins
Journal:  F1000Res       Date:  2014-04-03
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.